Q3 2024 EPS Estimates for Agenus Inc. (NASDAQ:AGEN) Lifted by B. Riley

Agenus Inc. (NASDAQ:AGEN) – Research analysts at B. Riley raised their Q3 2024 earnings per share (EPS) estimates for shares of Agenus in a note issued to investors on Tuesday, August 13th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will earn ($0.90) per share for the quarter, up from their previous forecast of ($2.82). B. Riley has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Agenus’ current full-year earnings is ($10.73) per share. B. Riley also issued estimates for Agenus’ Q4 2024 earnings at $0.58 EPS, FY2024 earnings at ($6.27) EPS, FY2025 earnings at ($6.59) EPS, FY2026 earnings at ($4.96) EPS, FY2027 earnings at ($4.23) EPS and FY2028 earnings at ($0.93) EPS.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The company had revenue of $23.51 million for the quarter, compared to analysts’ expectations of $64.73 million. During the same period in the prior year, the company earned ($4.00) earnings per share.

AGEN has been the topic of a number of other reports. HC Wainwright cut Agenus from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $40.00 to $9.00 in a report on Thursday, July 18th. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $35.00 to $8.00 in a research report on Friday, July 19th. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Baird R W downgraded Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. Finally, William Blair cut Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.50.

Agenus Price Performance

Agenus stock opened at $5.28 on Friday. The firm has a 50 day simple moving average of $11.13 and a 200-day simple moving average of $11.77. The stock has a market cap of $110.87 million, a price-to-earnings ratio of -0.41 and a beta of 1.33. Agenus has a 1-year low of $4.41 and a 1-year high of $32.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AGEN. BNP Paribas Financial Markets increased its holdings in Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 84,477 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Agenus by 13.7% in the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after acquiring an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Agenus by 1,959.9% in the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 720,629 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 13,604 shares in the last quarter. Finally, Powell Investment Advisors LLC lifted its stake in Agenus by 21.8% during the first quarter. Powell Investment Advisors LLC now owns 243,500 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 43,500 shares during the last quarter. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.